The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
Comparing Costs and HRU for Tisagenlecleucel vs Axicabtagene Ciloleucel for DLBCL
Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.
Zanubrutinib Cost-effective and Cost Saving vs Ibrutinib in Waldenström Macroglobulinemia
Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib.
Investigators Document Muscle Loss During Immunochemotherapy for DLBCL
Investigators in a retrospective study of patients with diffuse large B-cell lymphoma (DLBCL) sought to understand the correlation between muscle loss and immunochemotherapy.
Addressing Disparities in Cancer Care and Beyond: What Can Be Done Now?
Conversations on CAR T: Study of Checkpoint Inhibitors After Transplant Bolsters Case for CAR T, Skarbnik Says
Conversations on CAR T: UAB’s Mehta Discusses Opportunities and Challenges
Elevated Risks of NHL, Lung Cancer Increase Mortality in Recipients of Organ Transplant
People who receive organ transplants have an elevated risk of developing cancer, particularly lung cancer and non-Hodgkin lymphoma (NHL).
Review Outlines Progress on GE-Based Biomarkers for CML
A recently published review outlines progress made in discovering biomarkers for chronic myeloid leukemia (CML).
Patient Characteristics Impact Effectiveness of TKIs in CML and AEs Experienced
Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).
Second-Generation BTK Inhibitors Seek to Build Off Ibrutinib Success in CLL
These second-generation inhibitors include acalabrutinib, zanubrutinib, and tirabrutinib, and researchers hope they can overcome the off-target toxicity and treatment resistance that can be experienced with ibrutinib.
Better Knowledge Needed of Unmet Needs of Cancer Survivors
Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.
BTK Inhibition in CLL: Successes and Challenges
A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).
Zanubrutinib Gains Accelerated Approval in R/R Marginal Zone Lymphoma
This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene.
Posters Highlight Need for Psychosocial Support in Adolescent Survivors of Childhood Leukemia
Two posters being presented at the European Society for Medical Oncology Congress 2021 highlighted the need to provide long-term psychosocial support for adolescents who survive childhood leukemia.
Researchers Find Insight Into Risk of Developing AML
In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.
Data Support Once-Daily Dosing of Zanubrutinib for MCL
Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.
Ongoing Research Aims to Elucidate Underlying Drivers of HCL
Unlike most other cancers, the progression of hairy cell leukemia is largely driven by extended cell survival rather than increased proliferative cell fractions.
Study Examines Treatment Link to Transplant Complication in GVHD
Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.
FDA Approves Zanubrutinib in Adults With Waldenström Macroglobulinemia
The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.
Researchers Identify Potential Approach to Overcoming CLL CAR T-Cell Resistance
The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.
HSC Transplantation, Killer-Cell Combo May Lower Risk of GVHD in Leukemia
The meta-analysis collected findings from 11 studies, from which researchers determined statistical heterogeneity regarding the incidence of GVHD between patients receiving only HSC transplantation or only killer cell therapy, and patients receiving HSC transplantation in addition to killer cell therapy.
Study Reveals Poor Prognostic Factors Associated With DLBCL of the Urinary Tract
A recent study found that older age, male gender, lack of surgical resection or chemotherapy, and late-stage disease may be poor prognostic factors for diffuse large B-cell lymphoma (DLBCL) of the urinary tract.
AML Treatment Improves Complete Remission, Total Effectiveness Rates
The researchers of a new analysis argue that the treatments they investigated for acute myelogenous leukemia (AML) are worthy of clinical promotion based on their findings, which they say also provide evidence-based guidance for clinical practice.
Patients With AML May Acquire TP53 Mutations Over the Course of Therapy
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial.
Health Insurance, Blood Cancer Care, and Outcomes: A Literature Review
Conference Coverage: European Hematology Association 2021 Virtual Congress
Breast Cancer Drug May Also Treat Myelofibrosis, Reduce Bone Marrow Scarring
The breast cancer drug palbociclib may be able to treat myelofibrosis either alone or in combination with ruxolitinib.
Pediatric ALL Relapse May Be Caused by Mutations From Chemotherapy
Chemotherapy is standard care for pediatric acute lymphoblastic leukemia (ALL), but new research shows thiopurines can cause mutations that result in relapse.
Disparities Persist in the Long Term for 5-Year AYA Survivors of Hodgkin Lymphoma
Treatment-related modifications have resulted in improved long-term outcomes for all adolescent and young adult (AYA) survivors of Hodgkin lymphoma, but new research highlights that racial, ethnic, and socioeconomic status disparities persist in the long term.
Positive Results From SEQUOIA Analyses for Zanubrutinib in Treatment-Naive CLL and SLL
In an interim analyses of the phase 3 SEQUOIA trial, zanubrutinib had superior progression-free survival compared with bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
2 Clarke Drive Cranbury, NJ 08512